Venture Life Group PLC Directorate Change (2514W)
December 20 2021 - 10:13AM
UK Regulatory
TIDMVLG
RNS Number : 2514W
Venture Life Group PLC
20 December 2021
20 December 2021
Venture Life Group plc
("Venture Life" or the "Company")
Directorate Change
Venture Life (AIM: VLG), a leader in developing, manufacturing
and commercialising products for the self-care market, is pleased
to announce that Mr Daniel Wells, appointed as Chief Financial
Officer at the time of the trading update announcement on 1
December 2021, has joined the Board with immediate effect.
Further information on Daniel Wells
Daniel James Wells (aged 34) has in the last five years been a
director of The Green (Stoke Park) Management Company Limited and
is currently a director of Susandan Limited.
There is no further information on Daniel Wells required to be
disclosed under Schedule Two, paragraph (g) of the AIM Rules for
Companies.
For further information please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
+44 (0) 20 7397
Cenkos Securities plc (Nomad and Broker) 8900
Stephen Keys / Camilla Hume
Russell Kerr / Michael Johnson (Sales)
+44 (0) 20 7496
N+1 Singer (Joint Broker) 3000
Shaun Dobson / Alaina Wong (Corporate Finance)
Jonathan Dighe (Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in both the UK and
Italy, the Group's product portfolio includes some key products
such as the UltraDEX and Dentyl oral care product ranges, food
supplements for lowering cholesterol and maintaining brain
function, medical devices for women's intimate healthcare and
proctology and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK these are supplied
direct by the company, outside of the UK they are supplied by the
Group's international distribution partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABLBDDIGDDGBG
(END) Dow Jones Newswires
December 20, 2021 11:13 ET (16:13 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venture Life (LSE:VLG)
Historical Stock Chart
From Jul 2023 to Jul 2024